Zacks Investment Research on MSN
SENS stock up as Eversense 365 CGM wins European CE mark approval
Senseonics Holdings, Inc. SENS recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its ...
Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...
This diabetes technology offers a continuous stream of data to show a more complete picture of your blood sugars over time. This is different from a fingerstick meter ...
Emerging evidence points to potential benefits of continuous glucose monitoring (CGM) well beyond use as a management tool for people with diabetes who use insulin. Until recently, CGM use had been ...
Dr Anne Peters discusses updates in the ADA 2026 Standards of Care in Diabetes, focusing on the use of technology.
[28 January 2026]: Roche Diagnostics Middle East presented a landmark launch event revealing Accu-Chek SmartGuide, a ...
Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.
Apple Watch now supports glucose monitoring via CGMs like Dexcom G7, while Apple continues long-term work on non-invasive blood sugar tracking.
Experts discuss the clinical and practical factors that guide decision-making when recommending continuous glucose monitoring (CGM) vs traditional glucose monitoring for patients with type 2 diabetes.
South Wales Argus on MSN
Report: Continuous glucose monitoring helps manage blood sugar levels
A new report has found that continuous glucose monitoring has benefits beyond diabetes care ...
An international research team led by the Medical University of Vienna has shown that continuous glucose monitoring (CGM) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results